Summary
Edwards Lifesciences Corporation (EW) announced a significant strategic shift at its 2023 Investor Conference, detailing plans to spin off its Critical Care product group by the end of 2024. This move is intended to be a tax-free transaction, allowing the company to focus on its core transcatheter aortic valve replacement (TAVR) and transcatheter mitral and tricuspid therapies (TMTT) businesses, while the Critical Care segment will operate as an independent entity. Investors should note that further details regarding the spin-off, including a Form 10 filing with the SEC, are anticipated in mid-2024. In addition to the strategic spin-off, the company's Board of Directors has approved an additional $1 billion in share repurchase authorization. This signals continued confidence in the company's financial health and commitment to returning capital to shareholders. The spin-off is expected to unlock value and allow for more focused capital allocation and strategic growth opportunities for both the remaining Edwards Lifesciences and the new independent Critical Care company.
Key Highlights
- 1Edwards Lifesciences intends to spin off its Critical Care product group in a tax-free transaction by the end of 2024.
- 2The spin-off aims to allow Edwards Lifesciences to focus on its core TAVR and TMTT businesses.
- 3Katie Szyman, currently Corporate Vice President of Critical Care, will lead the new independent Critical Care company as CEO.
- 4A Form 10 filing with the SEC regarding the spin-off is planned for mid-2024.
- 5The Board of Directors approved an additional $1 billion in share repurchase authorization.
- 6This announcement was made in conjunction with the company's 2023 Investor Conference.